AstraZeneca’s (AZN) Hold Rating Reiterated at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft restated their hold rating on shares of AstraZeneca (LON:AZN) in a research note issued to investors on Tuesday, MarketBeat reports. Deutsche Bank Aktiengesellschaft currently has a £105 ($129.69) price target on the biopharmaceutical company’s stock.

A number of other analysts have also recently issued reports on AZN. BMO Capital Markets restated an outperform rating on shares of AstraZeneca in a research note on Monday, February 12th. JPMorgan Chase & Co. restated an overweight rating on shares of AstraZeneca in a research note on Thursday, April 4th. UBS Group lowered their price target on shares of AstraZeneca from £107 ($132.16) to GBX 9,900 ($122.28) and set a sell rating on the stock in a research report on Monday, February 12th. Berenberg Bank reaffirmed a buy rating on shares of AstraZeneca in a research report on Wednesday, March 13th. Finally, Barclays reaffirmed an overweight rating and set a £125 ($154.40) price target on shares of AstraZeneca in a research report on Monday, April 8th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, AstraZeneca has an average rating of Moderate Buy and a consensus price target of £116.86 ($144.34).

AstraZeneca Stock Performance

LON AZN opened at £120.26 ($148.54) on Tuesday. The firm has a 50-day moving average of £105.40 and a 200-day moving average of £104.44. The company has a debt-to-equity ratio of 75.70, a quick ratio of 0.59 and a current ratio of 0.82. The stock has a market cap of £186.40 billion, a PE ratio of 3,968.98, a P/E/G ratio of 0.89 and a beta of 0.19. AstraZeneca has a 52-week low of GBX 9,461 ($116.86) and a 52-week high of £122.10 ($150.82).

AstraZeneca Increases Dividend

The company also recently announced a dividend, which was paid on Monday, March 25th. Shareholders of record on Thursday, February 22nd were issued a GBX 156 ($1.93) dividend. This is a positive change from AstraZeneca’s previous dividend of $71.80. This represents a yield of 1.49%. The ex-dividend date was Thursday, February 22nd. AstraZeneca’s dividend payout ratio (DPR) is currently 7,524.75%.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.